Guilhem Richard

Company: EpiVax, Inc

Job title: Chief Scientific Officer & Chief Technology Officer

Seminars:

Beyond Neoantigens: Optimizing Antigen Cassette Design for Enhanced Vaccine Efficacy 2:00 pm

The Ancer® neoantigen discovery platform identifies high-quality effector neoantigens, filters out inhibitory sequences, and generates string-of-beads designs for oligonucleotide-based cancer vaccines Neoantigen cassette design is a non-trivial exercise, with parameters such as number of neoantigens, ordering, and inclusion of trafficking signals having a significant impact on mRNA vaccine immunogenicity and efficacyRead more

day: Pre-Conference Focus Day